Sesen Bio Inc

Sesen Bio — Merger or Acquisition (September 2022)

26 slides from Sesen Bio's merger presentation, Sep 27, 2022

  1. Slide 1: Harnessing the Power of Engineered Macrophages

    HARNESSING THE POWER OF ENGINEERED MACROPHAGES Carisma Therapeutics September 2022

  2. Slide 2: Carisma is Positioned for Success

    29/21/22 • Cutting edge research and bioengineering: o Proprietary platform for macrophage targeted therapies o Autologous/ allogeneic/ in-vivo modalities o Broad potential therapeutic applications, in oncology & beyond • Strong patent position covering all CAR-M therapies • Lead program demonstrati

  3. Slide 3: Macrophages: The Ultimate Multitasker

    39/21/22 Macrophages can: • Traffic to tumors/inflammation • Phagocytose • Initiate immune response • Present antigen to T-cells • Resolve fibrosis • Induce tissue regeneration • Resolve immune response Macrophages: The Ultimate Multitasker liver lung CNS wound infection tumor TAM M1 macrophage M2 m

  4. Slide 4: CAR-M Mechanism of Action: Multi-Pronged Attack on Cancer

    49/21/22 CAR-M Mechanism of Action: Multi-Pronged Attack on Cancer Carisma’s technology has the potential to address the key challenges involved in treating solid tumors TRAFFICKING AND PHAGOCYTOSIS IMMUNE ACTIVATION ANTIGEN PRESENTATION Target cell 1st time only CAR-M The activated T-cell recognize

  5. Slide 5: Carisma's Broad Myeloid Cell Engineering Platform

    59/21/22 Carisma’s Broad Myeloid Cell Engineering Platform Proprietary technology, leading macrophage engineering know-how, and strong IP portfolio ensure leadership position Monocyte & Macrophage Engineering Capabilities: • Proprietary platforms for durable macrophage engineering with Ad5f35 or Vpx

  6. Slide 6: Growing Number of Companies Targeting Macrophages for Solid Tumors

    C H E C K P O I N T I N H I B I T O R S • Block macrophage checkpoint inhibitors to unleash immune response 69/21/22 Growing Number of Companies Targeting Macrophages for Solid Tumors E N G I N E E R E D C E L L T H E R A P Y • Engineer myeloid cells to kill cancer, remodel the TME, and trigger adap

  7. Slide 7: Strong Patent Position Provides an Attractive Opportunity

    79/21/22 Strong Patent Position Provides an Attractive Opportunity • Worldwide patent coverage with issued and pending applications in major markets • Multiple issued US patents covering CAR- M composition of matter • Broad patent portfolio covering: o Viral and non-viral methods for engineering mon

  8. Slide 8: Carisma's Strategic Approach to Platform Expansion

    89/21/22 CARISMA’s Strategic Approach to Platform Expansion Initial focus on ex-vivo autologous approach expected to drive expansion into higher risk/ reward modalities In-Vivo Delivery Oncology • Solid Tumors • Heme Malignancy Autologous Allogeneic Non-Oncology • Liver Fibrosis • Neurodegeneration

  9. Slide 9: Moderna Partnership Validates Approach

    99/21/22 Moderna Partnership Validates Approach and Provides Significant Potential Value Inflection Points Promising data emerging with rapid execution on lead programs • Multiple development programs initiated, with goal of adding 2-3 new programs/ year • LNP delivery demonstrating high specificity

  10. Slide 10: Platform Enhancements Drive First-in-Class Pipeline

    109/21/22 Modality Product/Program Discovery Preclinical IND Clinical Partner O N C O L O G Y CT-0508 (HER2 CAR-Macrophage) CT-0508 (HER2 CAR-Macrophage with Pembrolizumab) CT-0508.1 (HER2 CAR-Monocyte) CT-1119 (Mesothelin CAR-M) CT-0729 (PSMA CAR-M) Discovery and Development Partnership (Up to 12 t

  11. Slide 11: CT-0508 Study 101 Interim Data Supports CAR-M Hypothesis

    F E A S I B I L I T Y • CT-0508 was successfully manufactured from autologous mobilized monocytes • Patient product demonstrated high CAR expression, purity, viability, M1 polarization and confirmed functionality • No lymphodepletion 119/21/22 CT-0508 Study 101 Interim Data Supports CAR-M Hypothesis

  12. Slide 12: CT-0508 Shown to Increase M1 Macrophage & T cell Infiltration in the TME

    129/21/22 CT-0508 Shown to Increase M1 Macrophage & T cell Infiltration in the TME Increased fraction of M1 macrophages N = 3 pts with paired biopsy scRNA SEQ data. C S F 3 C C L 2 0 IL 1 B IL 1 A N F K IAIL 6 T N F S c re e n in g W e e k 4 Patient 1 Myeloid Activation Significantly increased effec

  13. Slide 13: CT-0508 Shown to Induce Adaptive Anti-Tumor Immunity

    139/21/22 CT-0508 Shown to Induce Adaptive Anti-Tumor Immunity T cell clonality significantly increased within the tumor, indicating adaptive anti-tumor immunity Treatment emergent T cell clones infiltrate the TME, expand within the TME over time, and adopt a cytotoxic phenotype – demonstrating pote

  14. Slide 14: CAR-M Platform Development Strategy

    N e x t G e n C o n s t r u c t s Enhance CAR-M killing, cytokine release, & T cell priming • CAR modification (hinge & co-stimulation) + additional payloads C A R - M + P D 1 B l o c k a d e Overcome late-stage patients’ T cell exhaustion • Phase I/II CT-0508 + Pembrolizumab study expected to start

  15. Slide 15: CT-0508 Potential to Reverse Immune Checkpoint Blockade Resistance

    159/21/22 CT-0508 Has Potential to Reverse Immune Checkpoint Blockade Resistance and Demonstrates Robust Synergy* 0 60 120 0 50 100 Days S u rv iv a l p ro b a b il it y ( % ) CTRL CAR-M CAR-M + aPD-1 aPD-1 ✱✱✱✱ ✱ CT-0508 + Keytruda® Study planned for 2H 2022 1 Synergistic anti-tumor activity Profou

  16. Slide 16: Carisma's CAR Monocyte Platform

    169/21/22 Carisma’s CAR Monocyte Platform Rapid manufacture & durable persistence 2 Rapid Manufacturing Process Key Characteristics* • Improved cell dose and dosing flexibility • Improved trafficking • Improved persistence • Improved killing • Improved cytokine release • Improved potential for antig

  17. Slide 17: Next Gen CAR-M Discovery

    179/21/22 Next Gen CAR-M Discovery Potential to increase potency & functionality 3 Antibody Phagocytic Receptor CTX-001 Innate Immune Activating Receptor* Phagocytosis Second Signal * Example: CD40, TLR2, TLR4, MyD88, Dectin-1, etc. Low “Stress Test” E:T Ratio: Adding MYD88/CD40 significantly increa

  18. Slide 18: Off-the-Shelf iPSC Derived Myeloid Cells

    189/21/22 Off-the-Shelf iPSC Derived Myeloid Cells Expandable, allogeneic, and potentially broadly applicable 4 Tumor Alone iPSC Macrophage iPSC CAR-M T u m o r B u rd e n Time (hours) iCAR-M anti-tumor function in-vitro Production of iCAR-M >1,000x expansion iP S C M a c ro p h a g e GMP = Good man

  19. Slide 19: Directly Reprogramming Myeloid Cells In Vivo with mRNA/LNP

    199/21/22 Directly Reprogramming Myeloid Cells In Vivo with mRNA/LNP • Myeloid tropic LNP have demonstrated specificity and efficient transfection in vivo • LNP have proven safety profile in previous clinical studies; repeat dosing well tolerated • High CAR expression and function in vitro • Lead id

  20. Slide 20: Platform Enables Potential Non-Oncology Applications

    209/21/22 Platform Enables Potential Non-Oncology Applications Significant opportunity for strategic partnerships 1 Anti-inflammatory, anti-fibrotic macrophages: • Modality: Auto/Allo Cell Therapy • Potential indication: Liver Fibrosis • Payload: Immunosuppressive cytokine + anti-fibrotic enzyme 2 I

  21. Slide 21: Strong Leadership Team and Advisors

    219/21/22 Strong Leadership Team and Advisors Deep research, clinical and operational expertise in cell and gene therapy and oncology Board of Directors • Sanford Zweifach – Chairperson • Briggs Morrison – Independent Director • Margarita Chavez – AbbVie Ventures • Bjorn Odlander – HealthCap • Regin

  22. Slide 22: Operating Plan and Corporate Milestones

    229/21/22 Operating Plan and Corporate Milestones Capital efficient R&D program designed to reach significant value inflection points over next 18 months Complete expanded CT-0508 Phase I study • Cohort 2: Bolus dosing • IP Administration • Anti-PD1 combination Advance our engineered macrophage plat

  23. Slide 23: Transaction Structure

    Transaction Structure • Carisma / Sesen Bio business combination • Carisma valuation of $196M • Sesen Bio valuation of $140M (~$125M of cash) • Concurrent Financing: Private placement of $30M to be funded into Carisma immediately prior to closing of the business combination • Implied ownership split

  24. Slide 24: Corporate Summary

    249/21/22 Corporate Summary Significant opportunity to become a breakthrough therapeutics company Proprietary engineered macrophage platform Emerging pipeline of oncology CAR-Ms Validating partnership and clinical data Experienced leadership team and advisors Multiple potential value catalysts over

  25. Slide 25: Risk Factors

    259/21/22 Risk Factors The list below of risk factors has been prepared solely for purposes of Carisma’s proposed private placement transaction (the “Private Placement”), which is expected to close concurrent with the proposed merger transaction (the “Merger”) by and among Sesen Bio, Inc. (“Sesen Bi

  26. Slide 26: Risk Factors (continued)

    269/21/22 • Carisma relies, and expects to continue to rely, on third parties for the manufacture of its product candidates for preclinical studies and clinical trials, as well as for commercial manufacture if any of its product candidates receive marketing approval. This reliance on third parties m

Sesen Bio — Merger or Acquisition (September 2022) on 6ix